Related Experiment Video

Updated: Aug 13, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Kidney cancer: identification of novel targets for therapy

R H Weiss1, P-Y Lin

  • 1Department of Internal Medicine and Cancer Center, Division of Nephrology, University of California, Davis, California 95616, USA. rhweiss@ucdavis.edu

Kidney International
|January 13, 2006
PubMed

Insights

Kidney cancer is uncommon but serious, especially when metastatic. New molecular insights are driving promising, novel therapeutic approaches for kidney cancer patients.

Area of Science:

  • Oncology
  • Nephrology

Background:

  • Kidney cancer is relatively rare but occurs in patients with renal disease.
  • Metastatic kidney cancer has a poor survival rate with conventional therapy.
  • Early detection often occurs incidentally during nephrologic work-up or via paraneoplastic signs.

Purpose of the Study:

  • To review the current diagnosis and therapy of kidney cancer.
  • To summarize novel treatments targeting molecular pathways in kidney cancer.

Main Methods:

  • Literature review of kidney cancer diagnosis and treatment.
  • Analysis of emerging molecular mechanisms in kidney cancer oncogenesis.

Main Results:

  • Surgical treatment is curative for localized kidney cancer.
  • Metastatic kidney cancer presents significant therapeutic challenges.
  • Novel therapies are being developed based on molecular pathway understanding.

Conclusions:

  • Emerging knowledge of kidney cancer molecular mechanisms is leading to promising new treatments.
  • A comprehensive review of current and novel kidney cancer therapies is presented.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.